A Study of LY3561774 in Participants With Mixed Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT05256654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05256654
  • EudraCT 2021-005407-13
Other papers using this trial's data
  • Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial Lancet (London, England), 2025-05-03 DOI, PubMed 40179932 PubMed links an erratum for this paper. Erratum: PMID 40318876

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Japan, Mexico, Poland, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05256654. Randomized; double masking; primary purpose treatment. Start 2022-07-20 (actual); primary completion 2024-03-04 (actual). Results posted on 2025-03-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3561774 in Participants With Mixed Dyslipidemia
Acronym
PROLONG-ANG3
Condition
Dyslipidemias
Condition
Lipid Metabolism Disorders
Condition
Metabolic Diseases
Condition
Hyperlipoproteinemia
Intervention (Drug)
LY3561774
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05256654
Content hash
10adb8c5f430ba14da0dd2b459ecd4b38f6f6c64eba0bbda75ce44a07886b592